Control Bionics (ASX:CBL) lines up 1,000 NextLevel devices and an Apple BCI release

A US billing code and German insurance pathway turn three platforms into one commercial story

Investor presentations from small-cap medtech companies usually try to do one job, which is to convince the market that the technology is real. Today’s update from Control Bionics (ASX:CBL) is trying to do something harder. It is trying to show that three different platforms are starting to find paying customers at the same time.

The headline items are a letter of intent for 1,000 NextLevel iOS communication devices with US$100,000 upfront, a US distribution agreement with Tobii Dynavox and PRC-Saltillo signed in January, and German HMV insurance coverage locked in February. On top of that, the NeuroStrip sensor is being evaluated by AFL and NRL clubs, the Australian Institute of Sport and Ohio University.

There is also a software angle. Control Bionics says it is developing Apple BCI protocol integration with a global release targeted for Q3 2026, which puts a credible distribution surface under its neural interface technology. That is a lot of moving parts to unpack, so let us work through what actually matters for investors.

The US billing code is the unlock everyone underestimated

The single most important commercial milestone here is not the LOI or the Apple integration. It is the E2513 HCPCS billing code that the US allocated to Control Bionics’ assistive communication category, because that is what makes the Tobii Dynavox and PRC-Saltillo distribution deal economically viable.

Without a reimbursement code, every sale needs to be funded out of pocket or fought for case by case. With one, the two largest US assistive communication distributors can plug Control Bionics devices into existing insurance billing workflows. Germany’s HMV listing does the same job in Europe.

That moves the company from a sales-led model to a reimbursement-led one. It is a fundamentally different business, and it is the reason the distribution agreements signed earlier this year should start showing up in revenue from here.

The 1,000-unit LOI is real, but US$100 per device upfront is the tell

The April LOI for 1,000 NextLevel iOS-based communication devices with US$100,000 upfront sounds substantial. The skeptical read is that US$100 per device upfront is well below typical hardware pricing for assistive communication devices, which usually sit in the thousands per unit.

Our take is that this is a partner-led distribution deal where Control Bionics is supplying the technology stack and the partner is taking the commercial risk on the end-user pricing. That is a sensible model for a small company without a sales force, but it means the headline unit number will not translate directly into headline revenue.

Investors should watch the next quarterly cash flow report for the actual receipt of the US$100,000 and any commentary on conversion of the LOI into a firm purchase order.

NeuroStrip is the optionality, not the base case

The NeuroStrip evaluations with elite sports organisations are the kind of customer list that gets attention. AFL and NRL clubs, the AIS and Ohio University all running structured programs is a credible validation pathway, and the Japanese Stroke Lab study showing a 39% reduction in muscle overactivity gives the clinical side something to point at.

But evaluation programs are not purchase orders. The NeuroStrip business is still pre-commercial in any meaningful revenue sense, and the path from sports science trial to recurring enterprise contracts in elite sport is notoriously slow.

We would treat NeuroStrip as the call option in this story. The assistive technology business with US and German reimbursement is the base case that needs to fund the next 18 months.

The Investors Takeaway for Control Bionics

Today’s update is genuinely a step forward. A US billing code, a German insurance pathway, two top-tier US distribution partners and a credible Apple integration timeline for Q3 2026 is more commercial scaffolding than this company has ever had in place at one time.

The question now is conversion speed. Distribution agreements and insurance codes only matter when units start shipping through them at scale, and the next two quarterly reports will tell investors whether the reimbursement-led model is delivering revenue at a pace that justifies the share register’s patience. Readers can find more in-depth coverage of ASX-listed medtech names at stocksdownunder.